BAVA Bavarian Nordic A/S

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, July 3, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today received information about the following transactions of the company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such.

The transactions concern grant of restricted stock units as part of the remuneration of the board of directors as adopted at the ordinary general meeting.

1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameGerard van Odijk
2.Reason for the notification
a)Position/statusChairman of the Board of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 01,976
d)Aggregated information
  • Aggregated volume
  • Price
 



1,976

DKK 0
e)Date of the transaction2020-07-03
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameAnders Gersel Pedersen
2.Reason for the notification
a)Position/statusDeputy Chairman of the Board of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 01,185
d)Aggregated information
  • Aggregated volume
  • Price
 



1,185

DKK 0
e)Date of the transaction2020-07-03
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameErik G. Hansen
2.Reason for the notification
a)Position/statusMember of the Board of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0790
d)Aggregated information
  • Aggregated volume
  • Price
 



790

DKK 0
e)Date of the transaction2020-07-03
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NamePeter Kürstein
2.Reason for the notification
a)Position/statusMember of the Board of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0790
d)Aggregated information
  • Aggregated volume
  • Price
 



790

DKK 0
e)Date of the transaction2020-07-03
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameFrank Verwiel
2.Reason for the notification
a)Position/statusMember of the Board of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0790
d)Aggregated information
  • Aggregated volume
  • Price
 



790

DKK 0
e)Date of the transaction2020-07-03
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameElizabeth McKee Anderson
2.Reason for the notification
a)Position/statusMember of the Board of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0790
d)Aggregated information
  • Aggregated volume
  • Price
 



790

DKK 0
e)Date of the transaction2020-07-03
f)Place of the transactionOutside a trading venue



1.Details of the person discharging managerial responsibilities/person closely associated  
a)NameAnne Louise Eberhard
2.Reason for the notification
a)Position/statusMember of the Board of Bavarian Nordic A/S
b)Initial notification/AmendmentInitial notification
3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)NameBavarian Nordic A/S
b)LEI2138006JCDVYIN6INP51
4.Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument





Identification code
Restricted Stock Units





DK0015998017
b)Nature of the transactionGrant
c)Price(s) and volume(s)Price(s)Volume(s)
  DKK 0790
d)Aggregated information
  • Aggregated volume
  • Price
 



790

DKK 0
e)Date of the transaction2020-07-03
f)Place of the transactionOutside a trading venue

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains market-leading vaccines Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, licensed to Janssen. For more information visit .

Contacts

Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel:

US: Graham Morrell, Paddock Circle Advisors, , Tel:

Company Announcement no. 40 / 2020

Attachment

EN
03/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Bavarian Nordic A/S

 PRESS RELEASE

Indberetning af ledende medarbejdere og disses nærtståendes transaktio...

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer KØBENHAVN, Danmark, 9. maj 2025 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende medarbejdere og/eller personer/firmaer der er nærtstående til disse, hvilke hermed offentliggøres i overensstemmelse med §19 i Europa Parlamentets og Rådets forordning (EU) nr. 596/2014 samt Kommissionens Gennemførelsesforordning (EU) nr. 2016/523. Transaktionerne vedrør...

 PRESS RELEASE

Report of transactions of shares and related securities of Bavarian No...

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523. The tra...

 PRESS RELEASE

Bavarian Nordic offentliggør delårsregnskab for første kvartal 2025

Bavarian Nordic offentliggør delårsregnskab for første kvartal 2025 KØBENHAVN, Danmark, 9. maj 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag regnskab samt rapporterede på begivenheder for første kvartal 2025. Omsætningen i de første tre måneder sted med 62% til DKK 1.347 mio., hvilket afspejler en stærk udvikling i både Travel Health og Public Preparedness. Travel Health omsætning steg med 52% til DKK 680 mio. sammenlignet med første kvartal 2024, hvilket primært var drevet af øget efterspørgsel på vacciner mod rabies og flåtbåren hjernebetændelse (TBE).Public Preparedness...

 PRESS RELEASE

Bavarian Nordic Announces Interim Results for the First Three Months o...

Bavarian Nordic Announces Interim Results for the First Three Months of 2025 COPENHAGEN, Denmark, May 9, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three months increased by 62% to DKK 1,347 million, reflecting a strong performance in both Travel Health and Public Preparedness. Travel Health revenue increased by 52% to DKK 680 million compared to the first quarter of 2024, primarily driven by increased demand for rabies and tick-borne encephalitis (TBE) vaccines.Public...

 PRESS RELEASE

Bavarian Nordic er blevet tildelt kontraktoptioner fra den amerikanske...

Bavarian Nordic er blevet tildelt kontraktoptioner fra den amerikanske regering til produktion og levering af frysetørret koppe- og mpoxvaccine Værdien af tildelte kontraktoptioner udgør USD 143.6 mio.Sikrer produktion og levering af frysetørret JYNNEOS® til USA i 2026 KØBENHAVN, Danmark, 6. maj 2025 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Biomedical Advanced Research and Development Authority (BARDA), en del af Administration for Strategic Preparedness and Response (ASPR) ved U.S. Department of Health and Human Services (HHS) har udnyttet yderligere optioner til en værdi af...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch